Table 1. LPCAT1 immunostaining and breast cancer phenotype.

	LPCAT1 IHC result (%)					P
	N	Negative	Weak	Moderate	Strong
All cancers	1774	8.7	48.1	28.7	14.4
Histology						<0.0001
No special type (NST)	1277	7.8	46.0	30.0	16.2
Lobular carcinoma	228	11.4	62.7	20.2	5.7
Medullary carcinoma	60	6.7	35.0	40.0	18.3
Cribriform carcinoma	53	22.6	50.9	18.9	7.5
Tubular carcinoma	38	18.4	57.9	23.7	0.0
Papillary carcinoma	27	11.1	37.0	33.3	18.5
Mucinous carcinoma	50	2.0	54.0	34.0	10.0
Other and rare types*	41	4.9	39.0	29.3	26.8
Tumor stage						0.0176
pT1	638	9.2	52.2	27.9	10.7
pT2	856	7.9	46.6	28.6	16.8
pT3	101	10.9	47.5	22.8	18.8
pT4	202	8.4	42.6	34.2	14.9
Nodal status						0.2865
pN0	768	9.0	50.0	28.0	13.0
pN1	656	8.2	47.7	29.3	14.8
pN2	102	9.8	37.3	33.3	19.6
BRE grade						<0.0001
1	415	14.5	59.8	22.2	3.6
2	668	7.8	54.2	27.4	10.6
3	570	4.7	35.4	34.4	25.4
ER status						<0.0001
Negative	406	5.9	32.0	33.3	28.8
Positive	1289	9.7	52.8	27.2	10.3
PR status						<0.0001
Negative	1056	8.7	45.9	27.7	17.7
Positive	567	9.2	52.2	29.5	9.2
HER2 status						<0.0001
Normal	1153	9.1	51.2	28.4	11.3
Amplified	245	5.7	31.4	29.0	33.9

*including carcinoma with apocrine differentiation and metaplastic carcinoma of no special type.